Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa
Zubeida Salaam-Dreyer, Elizabeth M. Streicher, Frederick A. Sirgel, Fabrizio Menardo, Sònia Borrell, Miriam Reinhard, Anna Doetsch, Patrick Cudahy, Erika Mohr-Holland, Johnny Daniels, Anzaan Dippenaar, Mark P. Nicol, Sébastien Gagneux, Robin M. Warren, Helen Cox
Abstract
L430P mutation, 7 were phenotypically susceptible using the critical concentration of 0.5 μg/ml (range, 0.125 to 1 μg/ml). The majority (215/230 [93.5%]) of RMR isolates showed susceptibility to all other TB drugs, highlighting the potential benefits of WGS for simplified treatment. These data suggest that the evolution of RMR-TB differs from MDR-TB with a potential contribution from HIV infection.
Topics & Concepts
TuberculosisRifampicinMultiple drug resistanceVirologyMycobacterium tuberculosisMedicineBiologyMicrobiologyDrug resistancePathologyTuberculosis Research and EpidemiologyMycobacterium research and diagnosisPneumonia and Respiratory Infections